Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Arbutus Biopharma Corporation (ABUS) had Normalized Income after Taxes of $-12.53M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
$1.57M |
|
$-12.53M |
|
-- |
|
$1.57M |
|
$15.51M |
|
$-13.93M |
|
$1.40M |
|
$-12.53M |
|
$-12.53M |
|
$-12.53M |
|
$-12.53M |
|
$-12.53M |
|
|
Normalized Income after Taxes |
$-12.53M |
$-13.93M |
|
$-13.60M |
|
185.61M |
|
185.61M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$127.32M |
|
$3.31M |
|
$4.39M |
|
$131.71M |
|
$15.62M |
|
$2.86M |
|
$18.72M |
|
$34.34M |
|
$97.37M |
|
$97.37M |
|
$97.37M |
|
189.96M |
|
| Cash Flow Statement Financials | |
$-64.85M |
|
$22.95M |
|
$52.00M |
|
$26.29M |
|
$36.33M |
|
$10.04M |
|
$8.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.15 |
|
-- |
|
-- |
|
0.03 |
|
0.03 |
|
100.00% |
|
-885.20% |
|
-885.20% |
|
-- |
|
-796.19% |
|
-796.19% |
|
$-65.03M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.65 |
|
137.74 |
|
-12.87% |
|
-12.87% |
|
-9.52% |
|
-12.50% |
|
$0.51 |
|
$-0.35 |
|
$-0.35 |
|